Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society—Late Effects Study Group
Top Cited Papers
- 6 February 2004
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 42 (5) , 438-444
- https://doi.org/10.1002/pbc.20021
Abstract
Background Permanent consequences (PC) are often described among subjects with Langerhans cell histiocytosis (LCH) but data on the real incidence are scarce. Within the Histiocyte Society (HS), and in order to design a definitive late effects study, a retrospective survey was organized to describe the prevalence of PC among long‐term survivors of LCH. Methods Nine institutions contributed with their LCH patients having a minimum follow‐up of 3 years. Information was collected on their disease‐history, and on type and date of onset of any PC. Because of the retrospective type of this study, it was accepted that each institution might have used different criteria to assess PC. Results One hundred eighty‐two subjects were registered and in 95 (52%) at least 1 PC was reported. For some specific PC (e.g., anterior pituitary dysfunction) information was too scarce to provide reliable data. PC were more frequent among subjects with multisystem (MS) disease (71%), compared to those with single system (SS) disease (24%); P < 0.0001. The most frequently reported PC were diabetes insipidus (DI) (24%) orthopedic abnormalities (20%), hearing loss (13%), and neurological consequences (11.0%). Analysis of cumulative risk showed that some types of PC may become manifest more than 10 years from diagnosis. Conclusions This survey on selected cases of LCH survivors has confirmed that late sequels are frequent, and that they are even more common among those with MS LCH. Our findings highlight the need for long‐term and patient‐oriented follow‐up in children with LCH.Keywords
This publication has 24 references indexed in Scilit:
- Treatment of Multisystem Langerhans Cell Histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 StudiesKlinische Padiatrie, 2000
- LANGERHANS CELL HISTIOCYTOSIS: Retrospective Evaluation of 123 Patients at a Single InstitutionPediatric Hematology and Oncology, 1999
- Diabetes insipidus in langerhans cell histiocytosi: Results from the DAL‐HX 83 studyMedical and Pediatric Oncology, 1995
- Treatment strategy for disseminated langerhans cell histiocytosisMedical and Pediatric Oncology, 1994
- Langerhans cell histiocytosis in childhood: Results from the Italian cooperative AIEOP‐CNR‐H.X '83 studyMedical and Pediatric Oncology, 1993
- The Frequency and Natural History of Diabetes Insipidus in Children with Langerhans-Cell HistiocytosisNew England Journal of Medicine, 1989
- Quality of survival in histiocytosis X: A southwest oncology group studyMedical and Pediatric Oncology, 1980
- Histiocytosis X—an analysis of prognostic factorsThe Journal of Pediatrics, 1975
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958